219 related articles for article (PubMed ID: 25611103)
21. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
22. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
23. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.
Lamy A; Blanchard F; Le Pessot F; Sesboüé R; Di Fiore F; Bossut J; Fiant E; Frébourg T; Sabourin JC
Mod Pathol; 2011 Aug; 24(8):1090-100. PubMed ID: 21516079
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of real-time PCR-optimized oligonucleotide probe method and Sanger sequencing for detection of KRAS mutations in colorectal and lung carcinomas].
Qiu T; Ling Y; Chen Z; Shan L; Guo L; Lü N; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):599-602. PubMed ID: 23157827
[TBL] [Abstract][Full Text] [Related]
25. Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers.
Packham D; Ward RL; Ap Lin V; Hawkins NJ; Hitchins MP
Diagn Mol Pathol; 2009 Jun; 18(2):62-71. PubMed ID: 19430299
[TBL] [Abstract][Full Text] [Related]
26. High sensitive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles.
Huang Q; Wang GY; Huang JF; Zhang B; Fu WL
Mol Cell Probes; 2010 Dec; 24(6):376-80. PubMed ID: 20732413
[TBL] [Abstract][Full Text] [Related]
27. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.
Feigelson HS; Goddard KA; Johnson MA; Funk KC; Rahm AK; Kauffman TL; Chitale DA; Le Marchand L; Richards CS
BMC Res Notes; 2012 Apr; 5():196. PubMed ID: 22534075
[TBL] [Abstract][Full Text] [Related]
28. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
29. Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.
Hoorens A; Jouret-Mourin A; Sempoux C; Demetter P; De Hertogh G; Teugels E
Acta Gastroenterol Belg; 2010; 73(4):497-503. PubMed ID: 21299161
[TBL] [Abstract][Full Text] [Related]
30. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
[TBL] [Abstract][Full Text] [Related]
31. KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13.
Bihl MP; Hoeller S; Andreozzi MC; Foerster A; Rufle A; Tornillo L; Terracciano L
Diagn Mol Pathol; 2012 Mar; 21(1):14-23. PubMed ID: 22306671
[TBL] [Abstract][Full Text] [Related]
32. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.
Carotenuto P; Roma C; Rachiglio AM; Tatangelo F; Pinto C; Ciardiello F; Nappi O; Iaffaioli RV; Botti G; Normanno N
Pharmacogenomics; 2010 Aug; 11(8):1169-79. PubMed ID: 20712532
[TBL] [Abstract][Full Text] [Related]
33. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
34. Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.
Ogasawara N; Bando H; Kawamoto Y; Yoshino T; Tsuchihara K; Ohtsu A; Esumi H
Jpn J Clin Oncol; 2011 Jan; 41(1):52-6. PubMed ID: 20696815
[TBL] [Abstract][Full Text] [Related]
35. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
[TBL] [Abstract][Full Text] [Related]
36. Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer.
Wang J; Yang H; Shen Y; Wang S; Lin D; Ma L; Han X; Shi Y
Cancer Biomark; 2013; 13(2):89-97. PubMed ID: 23838137
[TBL] [Abstract][Full Text] [Related]
37. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.
Ausch C; Buxhofer-Ausch V; Oberkanins C; Holzer B; Minai-Pour M; Jahn S; Dandachi N; Zeillinger R; Kriegshäuser G
J Mol Diagn; 2009 Nov; 11(6):508-13. PubMed ID: 19797612
[TBL] [Abstract][Full Text] [Related]
38. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.
Kosmidou V; Oikonomou E; Vlassi M; Avlonitis S; Katseli A; Tsipras I; Mourtzoukou D; Kontogeorgos G; Zografos G; Pintzas A
Hum Mutat; 2014 Mar; 35(3):329-40. PubMed ID: 24352906
[TBL] [Abstract][Full Text] [Related]
39. KRAS testing in clinical laboratory: optimizing targeted therapy.
Miravalle L; Lefferts JA; Al-Haddad M; Tsongalis GJ; Cheng L
Cancer Genomics Proteomics; 2012; 9(5):337-41. PubMed ID: 22990113
[TBL] [Abstract][Full Text] [Related]
40. Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing.
Bando H; Tsuchihara K; Yoshino T; Kojima M; Ogasawara N; Fukushima H; Ochiai A; Ohtsu A; Esumi H
Jpn J Clin Oncol; 2011 Feb; 41(2):239-44. PubMed ID: 21113056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
